Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2018 Earnings Results

Catalyst Pharmaceuticals Misses on EPS — Stock Down 2.78%

Catalyst Pharmaceuticals reported a loss per share of $0.08, which did not meet expectations. The stock fell by 2.78% in response to the earnings report, reflecting investor concerns about the company's current challenges and lack of revenue details. The absence of guidance may also contribute to uncertainty among investors about the company's future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.08	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious outlook, acknowledging current hurdles while stressing their commitment to future growth. They did not provide specific guidance for the upcoming quarters.

Management highlighted ongoing challenges but remains focused on long-term goals.

They emphasized the importance of upcoming product developments.

Catalyst Pharmaceuticals Misses on EPS — Stock Down 2.78%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Misses on EPS — Stock Down 2.78%

Key numbers

Management commentary